Syngene’s new biologics facility in the US

Our expanded biologics manufacturing facility in Baltimore, Maryland, marks a strategic step forward in meeting the growing needs of our global partners. With 50,000 liters of single-use bioreactor capacity and dedicated monoclonal antibody (mAb) and recombinant protein production lines, the facility enhances our ability to deliver seamless, end-to-end services—from large molecule discovery and development to commercial-scale manufacturing.

This addition reinforces Syngene’s commitment to delivering scalable, high-quality biologics solutions to global markets.

Let's connect to accelerate your biologics

How this helps our customers

Designed to meet the growing demand for biologics in the US

Greater proximity to US clients

Total 50,000 L SUB capacity across US and India

mAb and recombinant protein manufacturing lines

Upto 4,000 L single use bioreactors

Dedicated mammalian cell culture

Full QC suite in US with viral clearance testing in India

Integrated delivery from multiple global sites

With our multiple biologics development and manufacturing sites, we offer a unified global supply chain ensuring continuity, flexibility, and reliability for clinical and commercial programs.

Why partner with Syngene

Ready to accelerate your mAb development?

Get the full overview of Syngene’s end-to-end CDMO services

© 2025 Syngene International Limited. All rights reserved

To view or email, Please share your details view

Your browser does not support this function.

To download, Please share your details

To view or email, Please share your details view

To download, Please share your details